AR goggles could help surgeons spot cancer cells left behind during breast cancer surgery
NCT ID NCT07696754
First seen Jul 10, 2026 · Last updated Jul 10, 2026
Summary
This trial tests whether special augmented-reality goggles can help surgeons find lymph nodes that may be missed during breast cancer surgery. The goggles show a fluorescent dye that collects in lymph nodes, allowing the surgeon to re-examine the area after the planned removal is complete. Thirty patients having breast cancer surgery with lymph node removal will take part. The study measures how often this technique finds cancer-containing nodes that would otherwise have remained, which could improve cancer staging and treatment planning.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- Active substance
- Augmented-reality goggles with indocyanine green dye
- What this could lead to
- If successful, this approach could help surgeons remove more cancer-containing lymph nodes during breast cancer surgery, leading to more accurate staging and potentially better outcomes.
- What could go wrong
- This is a small early-stage study with only 30 participants. The goggles may not find additional nodes in many cases, and removing extra tissue could carry surgical risks. Results need confirmation in larger trials.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Phase
-
Not a phased trial
Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.
- Participants
-
About 30 people
The number the study aims to enrol. It can still change while the study runs.
- Expected to start
-
Jul 2026
An estimate. Start dates often move.
- Expected to finish
-
Dec 2027
An estimate. End dates often move.
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
- Ages
-
18 years and older
- Sex
-
Female participants only
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: * Histologically proven breast cancer * Age 18 years or older * Undergoing radical surgery (mastectomy or quadrantectomy) with complete axillary lymph node dissection * Provides written informed consent Exclusion Criteria: * Pregnancy * Neoadjuvant chemotherapy * Prior breast surgery * Iodine or seafood allergy * Indocyanine green (ICG) allergy * Declines or is unable to provide informed consent
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Breast cancer are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
How to take part
Only the study team decides who joins. These are the ways to reach them.
-
The places running it
1 site. The list below names each one and where it is.
-
The official record
ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.
-
A doctor treating you
A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.
Contacts and locations
Locations
-
University Clinic for Thoracic and Vascular Surgery, Faculty of Medicine, UKIM
Skopje, 1000, North Macedonia
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Retrospective analysis of pyrotinib in the treatment of HER2-Positive advanced breast cancer previously treated with trastuzumab and pertuzumab
- AI-Assisted opportunistic breast cancer screening using non-contrast chest CT in women undergoing health examination: a retrospective validation and prospective Single-Arm interventional study
- Single-Fraction very accelerated partial breast irradiation (sfVAPBI) in Low-Risk invasive or ductal in situ breast carcinoma - phase II multicenter trial
- Mind and body: does resilience leave a molecular mark in breast cancer?
- Which pain block works better for breast surgery?
- Can a Triple-Drug combo erase HER2-Positive breast tumors before surgery?